Search results for "MMR"

showing 10 items of 23 documents

Intelligence and Music: Lower Intelligent Quotient Is Associated With Higher Use of Music for Experiencing Strong Sensations

2020

Intelligence is a key psychological feature associated to emotion and perception. Listening to music is often linked to emotional experience and sensation seeking (SS), traits that have been shown overall negatively correlated with intelligence. In a sample of 53 musicians and 54 non-musicians, we assessed the use of music for experiencing strong emotions through the Music in Mood Regulation (MMR) and the intelligence quotient (IQ) by using the Wechsler Adult Intelligence Scale III (WAIS-III). We found a negative correlation between the full IQ score and the use of music for SS in both musician and non-musician groups. Furthermore, the use of music for SS was negatively correlated with Ver…

Literature and Literary TheoryVisual Arts and Performing ArtsMusic in Mood Regulation (MMR)media_common.quotation_subject05 social sciencesemotionhigh sensation seekingintelligenceWechsler Adult Intelligence Scale (WAIS)050105 experimental psychologyKey (music)03 medical and health sciences0302 clinical medicineFeature (computer vision)Perceptionmusic usageSensation seeking0501 psychology and cognitive sciencesActive listeningPsychology030217 neurology & neurosurgeryMusicQuotientCognitive psychologymedia_commonEmpirical Studies of the Arts
researchProduct

Hereditary common cancers: molecular and clinical genetics.

2001

This review focuses on the functional role and structural features of the genes involved in common hereditary cancers. Most of these tumors are sporadic and the genetic alterations responsible for their genesis take place over several cell generations; nevertheless, 5 to 10% of the human tumors are hereditary, with a rapid development. Cancer susceptibility genes have been classified as "gatekeepers" (e.g. RB1, ki-ras) and "caretakers" (e.g. hMLH1 and hMSH2, BRCA1). The first step in identifying individuals at high risk of developing a specific inherited form of cancer, and who should therefore undergo genetic tests, is the detailed construction of family history (an accurate cancer family …

MaleModels GeneticSettore MED/06 - Oncologia MedicaBRCA geneRisk AssessmentHereditary cancerPedigreeAPC geneNeoplasmsBiomarkers TumorAnimalsHumansFemaleGenes Tumor SuppressorGenetic Predisposition to DiseaseMMR genesAnticancer research
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct

Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.

2014

Abstract Background In July 2006, Priorix-Tetra™, a combined measles-mumps-rubella-varicella (MMRV) vaccine, was licensed in Germany. Since a postlicensure study had shown a more than twofold elevated risk of febrile convulsions (FC) after first dose vaccination with the combined MMRV vaccine ProQuad ® compared to separately administered MMR and V vaccines (MMR+V), the Paul-Ehrlich-Institute, the German regulatory agency for vaccine licensing and safety, requested a study investigating the risk of FC for Priorix-Tetra™. Methods We performed a matched cohort study based on claims data of more than 17 million insurees in the German Pharmacoepidemiological Research Database. All children born …

MalePediatricsmedicine.medical_specialtymedicine.vaccineSeizures FebrileChickenpox VaccineCohort StudiesGermanymedicineClinical endpointHumansVaccines CombinedFebrile convulsionsMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryConfoundingVaccinationPublic Health Environmental and Occupational HealthInfantOdds ratioVaccinationInfectious DiseasesImmunizationRelative riskChild PreschoolMolecular MedicineFemalebusinessMeasles-Mumps-Rubella VaccineVaccine
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-anal…

2016

ABSTRACT Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance. The aim of this paper is to identify the main factors associated with partial and full MMR vaccination uptake in European parents, and combine the different studies to obtain overall quantitative measures. This activity is included within the ESCULAPIO project, funded by the Italian Ministry of Health. ORs and CIs were extracted, sources of heterogeneity explored and publication bias assessed. Forty-five papers were retrieved for the qualitative study, 26 of which were i…

ParentsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinedeterminant; measles; mumps and rubella; parents; uptake; vaccine; Immunology and Allergy; Immunology; PharmacologyImmunologyReviewdeterminantSettore MED/42 - Igiene Generale E ApplicataMMR vaccineRubellaMeasles03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsHumansmeaslesmeasleImmunology and AllergyMedicinemumps and rubella030212 general & internal medicineMumpsRubellaPharmacologyPracticebusiness.industryHealth KnowledgeVaccinationPublication biasPatient Acceptance of Health Caremedicine.diseaseEuropeVaccinationparentdeterminant; measles; mumps and rubella; parents; uptake; vaccine; Europe; Health Knowledge Attitudes Practice; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Patient Acceptance of Health Care; Rubella; Vaccination; ParentsAttitudesuptakeMeta-analysisMarital statusbusinessMeasles-Mumps-Rubella VaccineDemographyHuman Vaccines & Immunotherapeutics
researchProduct

A combination vaccine against measles, mumps, rubella and varicella.

2008

A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…

Pediatricsmedicine.medical_specialtymedicine.vaccineMeaslesRubellaChickenpox VaccineChickenpoxmedicineHumansPharmacology (medical)Vaccines CombinedSeroconversionChildMumpsImmunization ScheduleRubellaPharmacologyAttenuated vaccineMMRV vaccinebusiness.industryVaccinationAntibody titerInfantGeneral Medicinemedicine.diseaseVirologyVaccinationTolerabilityChild PreschoolbusinessMeasles-Mumps-Rubella VaccineMeaslesDrugs of today (Barcelona, Spain : 1998)
researchProduct

The impact of mandatory vaccination law in Italy on mmr coverage rates in two of the largest italian regions (Emilia-romagna and sicily): An effectiv…

2020

Background: Vaccine hesitancy has increased worldwide, leading to reduction in vaccination coverage rates. In particular, reduction in the coverage for the trivalent Measles-Mumps-Rubella vaccine has led to an increase of measles cases. The aim of this study is to analyze the coverage rates for the MMR vaccine in the Emilia-Romagna Region (RER) and Sicily Region (SR) between 2009 and 2018, and to correlate any significant change to index events which could have modified the trend of vaccination rates. Methods: Official aggregate data on vaccination coverage at 24 months provided by the RER and the SR were analyzed through trend analysis and related to important index events. Results: The tw…

Pharmacologylcsh:RImmunologycoverage rateslcsh:MedicineMMR vaccinemedicine.diseaseMandatory vaccinationMeaslesArticleVaccinationMandatory vaccinationTrend analysisInfectious DiseasesGeographyVaccination coverageDrug DiscoverymedicinePharmacology (medical)Aggregate datamandatory vaccinationsCoverage rateVaccine hesitancyDemography
researchProduct

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

2022

Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-…

Settore MED/06 - Oncologia MedicaHematologyMMR deficiencyColorectal cancerMMRPD-1/PD-L1DNA Mismatch RepairTumor-agnostic therapyOncologyNeoplasmsSolid tumorsHumansMicrosatellite InstabilityImmunotherapyColorectal NeoplasmsMSI
researchProduct

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile

2009

Abstract Priorix-Tetra ™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR ( Priorix ™) and varicella ( Varilrix ™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into rou…

Varicella vaccineImmunization Secondarymedicine.vaccineAntibodies ViralRubellaMeaslesChickenpox VaccinemedicineHumansVaccines CombinedChildClinical Trials as TopicReactogenicityMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantvirus diseasesmedicine.diseaseVirologyVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular MedicinebusinessMeasles-Mumps-Rubella Vaccine
researchProduct